


Patent claims

1. A 6-carboxyphenyldihydropyridazinone derivative of the general formula (I)



in which

A, D, E and G are identical or different and
represent hydrogen, halogen, trifluoromethyl or hydroxyl, or represent
(C₁-C₆)-alkyl or represent (C₁-C₆)-alkoxy,

R¹ and R² are identical or different and represent hydrogen or represent (C₁-C₆)-alkyl,

R^3 represents radicals of the formulae $-OR^4$ or $-NR^5R^6$,

in which

R^4 denotes cycloalkyl having from 3 to 8 carbon atoms or (C_1-C_8) -alkyl which is optionally substituted by hydroxyl, (C_1-C_6) -alkoxy, cycloalkyl having from 3 to 8 carbon atoms or aryl having from 6 to 10 carbon atoms which, for its part, can be substituted, once to twice, identically or differently, by substituents which are selected from the group: halogen, (C_1-C_6) -alkoxy, hydroxyl or trifluoromethyl, or denotes (C_1-C_8) -alkyl which is optionally substituted by a group of the formula $-NR^7R^8$,

Amen.
A¹

Species	1960-1961	1962-1963	1964-1965	1966-1967	1968-1969	1970-1971	1972-1973	1974-1975	1976-1977	1978-1979	1980-1981	1982-1983	1984-1985	1986-1987	1988-1989	1990-1991	1992-1993	1994-1995	1996-1997	1998-1999	2000-2001	2002-2003	2004-2005	2006-2007	2008-2009	2010-2011	2012-2013	2014-2015	2016-2017	2018-2019	2020-2021	2022-2023	2024-2025	2026-2027	2028-2029	2030-2031	2032-2033	2034-2035	2036-2037	2038-2039	2040-2041	2042-2043	2044-2045	2046-2047	2048-2049	2050-2051	2052-2053	2054-2055	2056-2057	2058-2059	2060-2061	2062-2063	2064-2065	2066-2067	2068-2069	2070-2071	2072-2073	2074-2075	2076-2077	2078-2079	2080-2081	2082-2083	2084-2085	2086-2087	2088-2089	2090-2091	2092-2093	2094-2095	2096-2097	2098-2099	2100-2101	2102-2103	2104-2105	2106-2107	2108-2109	2110-2111	2112-2113	2114-2115	2116-2117	2118-2119	2120-2121	2122-2123	2124-2125	2126-2127	2128-2129	2130-2131	2132-2133	2134-2135	2136-2137	2138-2139	2140-2141	2142-2143	2144-2145	2146-2147	2148-2149	2150-2151	2152-2153	2154-2155	2156-2157	2158-2159	2160-2161	2162-2163	2164-2165	2166-2167	2168-2169	2170-2171	2172-2173	2174-2175	2176-2177	2178-2179	2180-2181	2182-2183	2184-2185	2186-2187	2188-2189	2190-2191	2192-2193	2194-2195	2196-2197	2198-2199	2200-2201	2202-2203	2204-2205	2206-2207	2208-2209	2210-2211	2212-2213	2214-2215	2216-2217	2218-2219	2220-2221	2222-2223	2224-2225	2226-2227	2228-2229	2230-2231	2232-2233	2234-2235	2236-2237	2238-2239	2240-2241	2242-2243	2244-2245	2246-2247	2248-2249	2250-2251	2252-2253	2254-2255	2256-2257	2258-2259	2260-2261	2262-2263	2264-2265	2266-2267	2268-2269	2270-2271	2272-2273	2274-2275	2276-2277	2278-2279	2280-2281	2282-2283	2284-2285	2286-2287	2288-2289	2290-2291	2292-2293	2294-2295	2296-2297	2298-2299	2300-2301	2302-2303	2304-2305	2306-2307	2308-2309	2310-2311	2312-2313	2314-2315	2316-2317	2318-2319	2320-2321	2322-2323	2324-2325	2326-2327	2328-2329	2330-2331	2332-2333	2334-2335	2336-2337	2338-2339	2340-2341	2342-2343	2344-2345	2346-2347	2348-2349	2350-2351	2352-2353	2354-2355	2356-2357	2358-2359	2360-2361	2362-2363	2364-2365	2366-2367	2368-2369	2370-2371	2372-2373	2374-2375	2376-2377	2378-2379	2380-2381	2382-2383	2384-2385	2386-2387	2388-2389	2390-2391	2392-2393	2394-2395	2396-2397	2398-2399	2400-2401	2402-2403	2404-2405	2406-2407	2408-2409	2410-2411	2412-2413	2414-2415	2416-2417	2418-2419	2420-2421	2422-2423	2424-2425	2426-2427	2428-2429	2430-2431	2432-2433	2434-2435	2436-2437	2438-2439	2440-2441	2442-2443	2444-2445	2446-2447	2448-2449	2450-2451	2452-2453	2454-2455	2456-2457	2458-2459	2460-2461	2462-2463	2464-2465	2466-2467	2468-2469	2470-2471	2472-2473	2474-2475	2476-2477	2478-2479	2480-2481	2482-2483	2484-2485	2486-2487	2488-2489	2490-2491	2492-2493	2494-2495	2496-2497	2498-2499	2500-2501	2502-2503</
---------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-------------

contd.
a¹

in which

R⁷ and R⁸ are identical or different and denote hydrogen, (C₁-C₆)-alkyl or benzyl,

or


R⁴ denotes vinyl or allyl,

or

R⁴ denotes aryl having from 6 to 10 carbon atoms which is optionally substituted, once to twice, identically or differently, by substituents which are selected from the group consisting of: halogen, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy or hydroxyl,

R⁵ denotes hydrogen or (C₁-C₄)-alkyl,

R⁶ denotes cycloalkyl having from 3 to 8 carbon atoms or a radical of the formula



or

aryl having from 6 to 10 carbon atoms or a 5- to 7-membered aromatic heterocycle having up to 3 heteroatoms from the series S, N and/or O, it being possible for the ring systems which are listed here to be optionally substituted, once to several times, identically or differently, by substituents which are selected from the group: halogen, trifluoromethyl, hydroxyl, (C₁-C₆)-alkoxy, carboxyl, (C₁-C₆)-alkoxycarbonyl,

*contd.
a¹*

(C₁-C₆)-alkyl and radicals of the formulae -SO₂-NR⁹R¹⁰ and
-(CO)_a-NR¹¹R¹²,

in which

R⁹, R¹⁰, R¹¹ and R¹² are identical or different and denote hydrogen or
(C₁-C₆)-alkyl,

and

a denotes a number 0 or 1,



or

R⁶ denotes (C₁-C₈)-alkyl which is optionally substituted, once to
twice, identically or differently, by substituents which are
selected from the group: halogen, trifluoromethyl, hydroxyl,
(C₁-C₆)-alkoxy, carboxyl, (C₁-C₆)-alkoxycarbonyl and aryl
having from 6 to 10 carbon atoms and a 5- to 7-membered
aromatic heterocycles having up to 3 heteroatoms from the
series S, N and/or O, in which the ring systems can be
optionally substituted, once to three times, identically or
differently, by (C₁-C₆)-alkyl, halogen, (C₁-C₆)-alkoxy,
(C₁-C₆)-alkoxycarbonyl, trifluoromethyl or by the radical
-CO-NH₂,


or

R⁵ and R⁶ form, together with the nitrogen atom, cyclic radicals of the
formulae

contd.
a¹



or



which, for their part, can be optionally substituted,

5 and the salts thereof,

with the exception, however, of the compound N-methyl-4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)benzamide.

10 2. A 6-carboxyphenyldihydropyridazinone derivative of the general formula (I) as claimed in claim 1,

in which

15 A, D, E and G are identical or different and represent hydrogen, fluorine, chlorine, bromine or trifluoromethyl,

R¹ and R² are identical or different and represent hydrogen or represent methyl,

20 R³ represents radicals of the formulae -OR⁴ or -NR⁵R⁶,

in which

25 R⁴ denotes cyclopropyl, cyclopentyl or cyclohexyl or denotes (C₁-C₆)-alkyl which is optionally substituted by hydroxyl, (C₁-C₄)-alkoxy, cyclopropyl, cyclopentyl,

contd.
a¹

cyclohexyl or phenyl which, for its part, can be substituted once to twice, identically or differently, by substituents selected from the group: fluorine, chlorine, bromine, (C₁-C₄)-alkoxy, hydroxyl or trifluoromethyl, or

denotes (C₁-C₆)-alkyl which is optionally substituted by a group of the formula -NR⁷R⁸,

in which

R⁷ and R⁸ are identical or different and denote hydrogen or (C₁-C₄)-alkyl,

or

R⁴ denotes allyl,

R⁵ denotes hydrogen or (C₁-C₃)-alkyl,

R⁶ denotes cyclopropyl, cyclopentyl or cyclohexyl or denotes phenyl, thienyl, thiazolyl, furyl or pyridyl, it being possible for the listed aromatic ring systems to be optionally substituted, once to twice, identically or differently, by substituents selected from the group: fluorine, chlorine, bromine, trifluoromethyl, hydroxyl, (C₁-C₃)-alkoxy, (C₁-C₃)-alkoxycarbonyl, (C₁-C₄)-alkyl and radicals of the formulae -SO₂NR⁹R¹⁰ and -(CO)_a-NR¹¹R¹²,

in which

R⁹, R¹⁰, R¹¹ and R¹² are identical or different and denote hydrogen or (C₁-C₄)-alkyl,

contd.
a¹

and

a denotes a number 0 or 1,

5

or

R⁶ denotes (C₁-C₆)-alkyl which are optionally substituted once to twice, identically or differently, by substituents selected from the group: fluorine, chlorine, bromine, trifluoromethyl, hydroxyl, (C₁-C₄)-alkoxy, (C₁-C₄)-alkoxycarbonyl, phenyl, pyridyl, naphthyl, furyl or thiazolyl, it being possible for the ring systems to be optionally substituted, once to twice, identically or differently, by fluorine, chlorine, methyl, methoxycarbonyl, trifluoromethyl or by a radical of the formula -CO-NH₂,



10

15

or

20

R⁵ and R⁶ form, together with the nitrogen atom, cyclic radicals of the formulae



or

25

and the salts thereof,

contd.
a¹

with the exception, however, of the compound N-methyl-4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)benzamide.

3. A 6-carboxyphenyldihydropyridazinone derivative of the general formula (I)
5 as claimed in claim 1,

in which

A, D, E and G represent hydrogen,

R¹ and R² are identical or different and
represent hydrogen or represent methyl,

R³ represents radicals of the formulae -OR⁴ or -NR⁵R⁶,

in which

R⁴ denotes cyclopropyl, cyclopentyl or cyclohexyl or
denotes (C₁-C₅)-alkyl which is optionally substituted by
(C₁-C₄)-alkoxy, cyclopropyl, cyclopentyl, cyclohexyl or
phenyl which, for its part, can be substituted, once to twice,
identically or differently, by substituents selected from the
group: fluorine, chlorine, (C₁-C₄)-alkoxy, hydroxyl or
trifluoromethyl, or

denotes (C₁-C₄)-alkyl which is optionally substituted by a
group of the formula -NR⁷R⁸,

in which

R⁷ and R⁸ are identical or different and denote hydrogen, benzyl or
methyl,

contd.
a¹

5

~~or~~~~R⁴ denotes allyl,~~~~R⁵ denotes hydrogen or (C₁-C₃)-alkyl,~~

10

~~R⁶ denotes cyclopropyl, cyclopentyl or cyclohexyl or
denotes naphthyl, phenyl, thienyl, thiazolyl, furyl or pyridyl,
the listed ring systems being optionally substituted once to
twice, identically or differently, by substituents selected from
the group: fluorine, chlorine, bromine, trifluoromethyl,
(C₁-C₃)-alkoxy, (C₁-C₃)-alkoxycarbonyl, (C₁-C₃)-alkyl and
radicals of the formulae -SO₂-NR⁹R¹⁰ and -(CO)_a-NR¹¹R¹²,~~

15

~~in which~~~~R⁹, R¹⁰, R¹¹ and R¹² are identical or different and denote hydrogen or
(C₁-C₄)-alkyl,~~

20

~~and~~~~a denotes a number 0 or 1,~~

25

~~or~~

30


~~R⁶ denotes (C₁-C₆)-alkyl which is optionally substituted by
substituents selected from the group: fluorine, chlorine,
trifluoromethyl, (C₁-C₃)-alkoxy, (C₁-C₃)-alkoxycarbonyl,
phenyl, pyridyl, naphthyl, furyl, thienyl or thiazolyl, the ring
systems optionally being substituted once to twice, identically~~

or differently, by fluorine, chlorine, methyl, methoxycarbonyl or trifluoromethyl or by a radical of the formula $-CO-NH_2$,

or

5

~~R⁵ and R⁶ form, together with the nitrogen atom, cyclic radicals of the formulae~~



10

and the salts thereof,

with the exception, however, of the compound N-methyl-4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)benzamide.

15

4. A 6-carboxyphenyldihydropyridazinone derivative of the general formula (I) as claimed in claim 1,

in which

20

A, D, E and G represent hydrogen,

R^3 represents the radical $-NR^5R^6$, where $R^5 = H$ or methyl and R^6 is as previously defined,

25


and the remaining radicals have the previously mentioned meaning.

contd.
a¹

5. A process for preparing 6-carboxy-phenyl-dihydropyridazinone derivatives as claimed in claims 1 to 4, characterized in that

[A] in the case where R³ represents the radical of the formula -OR⁴ in the above general formula (I),


compounds of the general formula (II)



in which

A, D, R¹ and R² have the abovementioned meaning,

are initially converted, by reaction with carboxylic acid-activating reagents, using customary methods, into the compounds of the general formula (IV)




in which

A, D, R¹ and R² have the abovementioned meaning,

and

contd.
a¹

represents an activating radical, preferably chlorine or imidazolyl,
and, in a second step, reacted with compounds of the general formula
(III)



in which


R^4 has the abovementioned meaning,

in inert solvents, where appropriate in the presence of a base,

or

[B] in the case where R^3 represents the radical of the formula $-\text{NR}^5\text{R}^6$ in
the above general formula (I),

compounds of the general formula (II) are initially converted, by reaction
with carboxylic acid-activating reagents, and using customary methods, into
the compounds of the general formula (IV)



in which

A , D , R^1 and R^2 have the abovementioned meaning.


contd.
a¹

and

L represents an activating radical, preferably chlorine or imidazolyl,

5

and, in a second step, reacted with amides of the general formula (V)



10

in which

R⁵ and R⁶ have the abovementioned meaning,

in inert solvents.

15

6. A medicament or pharmaceutical composition which comprises at least one compound as claimed in claims 1 to 4 and also one or more pharmacologically harmless auxiliary and carrier substances.

redund.

20

7. A medicament or pharmaceutical composition as claimed in claim 6 for the prophylaxis and/or treatment of anemias.

25

8. A medicament or pharmaceutical composition as claimed in claim 6 or 7 for treating premature baby anemias, anemias associated with chronic renal insufficiency, anemias following chemotherapy and anemias in HIV patients.


9. A medicament or pharmaceutical composition as claimed in claim 6 for stimulating the erythropoiesis of individuals donating their own blood.

30

10. The use of 6-carboxyphenyldihydropyridazinone derivatives of the general formula (I)

Ammon.
a²

contd.
a²



in which

5

A , D , E and G are identical or different and represent hydrogen, halogen, trifluoromethyl or hydroxyl, or represent (C_1-C_6) -alkyl or represent (C_1-C_6) -alkoxy,

10

R^1 and R^2 are identical or different and represent hydrogen or represent (C_1-C_6) -alkyl,

R^3 represents radicals of the formulae $-OR^4$ or $-NR^5R^6$,

in which

15

R^4 denotes cycloalkyl having from 3 to 8 carbon atoms or (C_1-C_8) -alkyl which is optionally substituted by hydroxyl, (C_1-C_6) -alkoxy, cycloalkyl having from 3 to 8 carbon atoms or aryl having from 6 to 10 carbon atoms which, for its part, can be substituted, once to twice, identically or differently, by substituents which are selected from the group: halogen, (C_1-C_6) -alkoxy, hydroxyl or trifluoromethyl, or

20

denotes (C_1-C_8) -alkyl which is optionally substituted by a group of the formula $-NR^7R^8$,

25

in which

contd.
a²

R⁷ and R⁸ are identical or different and denote hydrogen, (C₁-C₆)-alkyl or benzyl,

or


R⁴ denotes vinyl or allyl,

or

R⁴ denotes aryl having from 6 to 10 carbon atoms which is optionally substituted, once to twice, identically or differently, by substituents which are selected from the group consisting of: halogen, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy or hydroxyl,

R⁵ denotes hydrogen or (C₁-C₄)-alkyl,

R⁶ denotes cycloalkyl having from 3 to 8 carbon atoms or a radical of the formula



or

aryl having from 6 to 10 carbon atoms or a 5- to 7-membered aromatic heterocycle having up to 3 heteroatoms from the series S, N and/or O, it being possible for the ring systems which are listed here to be optionally substituted, once to several times, identically or differently, by substituents which are selected from the group: halogen, trifluoromethyl, hydroxyl, (C₁-C₆)-alkoxy, carboxyl, (C₁-C₆)-alkoxycarbonyl, (C₁-C₆)-alkyl and radicals of the formulae -SO₂-NR⁹R¹⁰ and -(CO)_a-NR¹¹R¹²,

in which

contd.
a²

5

R^9 , R^{10} , R^{11} and R^{12} are identical or different and denote hydrogen or (C₁-C₆)-alkyl,

and

a denotes a number 0 or 1,

or

10

R^6 denotes (C₁-C₈)-alkyl which is optionally substituted, once to twice, identically or differently, by substituents which are selected from the group: halogen, trifluoromethyl, hydroxyl, (C₁-C₆)-alkoxy, carboxyl, (C₁-C₆)-alkoxycarbonyl and aryl having from 6 to 10 carbon atoms and a 5- to 7-membered aromatic heterocycle having up to 3 heteroatoms from the series S, N and/or O, in which the ring systems can be optionally substituted, once to three times, identically or differently, by (C₁-C₆)-alkyl, halogen, (C₁-C₆)-alkoxy, (C₁-C₆)-alkoxycarbonyl, trifluoromethyl or by the radical -CO-NH₂,

15


20

or

25

R^5 and R^6 form, together with the nitrogen atom, cyclic radicals of the formulae

contd.
a²



which, for their part, can be optionally substituted,

5 and the salts thereof,

for preparing medicaments or pharmaceutical compositions for the prophylaxis and/or treatment of anemias.

10 11. The use of 6-carboxyphenyldihydropyridazinone derivatives of the general formula (I) as claimed in claim 10,

in which

15 A, D, E and G are identical or different and represent hydrogen, fluorine, chlorine, bromine or trifluoromethyl,

R¹ and R² are identical or different and represent hydrogen or represent methyl,

20

R³ represents radicals of the formulae -OR⁴ or -NR⁵R⁶,

in which

25

R⁴ denotes cyclopropyl, cyclopentyl or cyclohexyl or denotes (C₁-C₆)-alkyl which is optionally substituted by hydroxyl, (C₁-C₄)-alkoxy, cyclopropyl, cyclopentyl,

contd.
a²

or phenyl which, for its part, can be substituted once to twice, identically or differently, by substituents selected from the group: fluorine, chlorine, bromine, (C₁-C₄)-alkoxy, hydroxyl or trifluoromethyl, or

denotes (C₁-C₆)-alkyl which is optionally substituted by a group of the formula -NR⁷R⁸,

in which

R⁷ and R⁸ are identical or different and denote hydrogen or (C₁-C₄)-alkyl,

or

R⁴ denotes vinyl or allyl,

R⁵ denotes hydrogen or (C₁-C₃)-alkyl,

R⁶ denotes cyclopropyl, cyclopentyl or cyclohexyl or denotes phenyl, thienyl, thiazolyl, furyl or pyridyl, it being possible for the listed aromatic ring systems to be optionally substituted, once to twice, identically or differently, by substituents selected from the group: fluorine, chlorine, bromine, trifluoromethyl, hydroxyl, (C₁-C₃)-alkoxy, (C₁-C₃)-alkoxycarbonyl, (C₁-C₄)-alkyl and radicals of the formulae -SO₂NR⁹R¹⁰ and -(CO)_a-NR¹¹R¹²,

in which

R⁹, R¹⁰, R¹¹ and R¹² are identical or different and denote hydrogen or (C₁-C₄)-alkyl,

contd.
a²

5

10

15

20

25

and


a denotes a number 0 or 1,

or

R⁶ denotes (C₁-C₆)-alkyl which are optionally substituted once to twice, identically or differently, by substituents selected from the group: fluorine, chlorine, bromine, trifluoromethyl, hydroxyl, (C₁-C₄)-alkoxy, (C₁-C₄)-alkoxycarbonyl, phenyl, pyridyl, naphthyl, furyl or thiazolyl, it being possible for the ring systems to be optionally substituted, once to twice, identically or differently, by fluorine, chlorine, methyl, methoxycarbonyl, trifluoromethyl or by a radical of the formula -CO-NH₂,

or

R⁵ and R⁶ form, together with the nitrogen atom, cyclic radicals of the formulae



which are in turn optionally substituted,

and the salts thereof,

contd.
a²

for preparing medicaments or pharmaceutical compositions for the prophylaxis and/or treatment of anemias.

- 5 12. The use of 6-carboxyphenyldihydropyridazinone derivatives of the general formula (I) as claimed in claim 10,

in which

10 A, D, E and G represent hydrogen,

R¹ and R² are identical or different and
represent hydrogen or represent methyl,

15 R³ represents radicals of the formulae -OR⁴ or -NR⁵R⁶,

in which

20 R⁴ denotes cyclopropyl, cyclopentyl or cyclohexyl or
denotes (C₁-C₅)-alkyl which is optionally substituted by
(C₁-C₄)-alkoxy, cyclopropyl, cyclopentyl, cyclohexyl or
phenyl which, for its part, can be substituted, once to twice,
identically or differently, by substituents selected from the
group: fluorine, chlorine, (C₁-C₄)-alkoxy, hydroxyl or
25 trifluoromethyl, or

denotes (C₁-C₄)-alkyl which is optionally substituted by a
group of the formula -NR⁷R⁸,

30 in which

contd.
A²

5

R^7 and R^8 are identical or different and denote hydrogen, benzyl or methyl,

or

R^4 denotes allyl,

R^5 denotes hydrogen or (C₁-C₃)-alkyl,

10

R^6 denotes cyclopropyl, cyclopentyl or cyclohexyl or denotes naphthyl, phenyl, thienyl, thiazolyl, furyl or pyridyl, the listed ring systems being optionally substituted once to twice, identically or differently, by substituents selected from the group: fluorine, chlorine, bromine, trifluoromethyl, (C₁-C₃)-alkoxy, (C₁-C₃)-alkoxycarbonyl, (C₁-C₃)-alkyl and radicals of the formulae $-SO_2-NR^9R^{10}$ and $-(CO)_a-NR^{11}R^{12}$,

15

in which

20

R^9 , R^{10} , R^{11} and R^{12} are identical or different and denote hydrogen or (C₁-C₄)-alkyl,

and

25

a denotes a number 0 or 1,

or

30

R^6 denotes (C₁-C₆)-alkyl which is optionally substituted by substituents selected from the group: fluorine, chlorine, trifluoromethyl, (C₁-C₃)-alkoxy, (C₁-C₃)-alkoxycarbonyl, phenyl, pyridyl, naphthyl, furyl, thienyl or thiazolyl, the ring

contd.,
a²


ring systems optionally being substituted once to twice, identically or differently, by fluorine, chlorine, methyl, methoxycarbonyl or trifluoromethyl or by a radical of the formula $-CO-NH_2$,

5

or

R^5 and R^6 form, together with the nitrogen atom, cyclic radicals of the formulae

10



which are in turn optionally substituted,

15

and the salts thereof,

for preparing medicaments or pharmaceutical compositions for the prophylaxis and/or treatment of anemias.

20

13. The use of 6-carboxyphenyldihydropyridazinone derivatives of the general formula (I) as claimed in claim 10,

in which

25

A, D, E and G represent hydrogen,

contd.
a²

R^3 represents the radical $-NR^5R^6$, where $R^5 = H$ or methyl and R^6 is as previously defined,

and the remaining radicals have the previously given meaning,

and the salts thereof,

for preparing medicaments or pharmaceutical compositions for the prophylaxis and/or treatment of anemias

14. The use as claimed in one of claims 10 to 13 for preparing medicaments or pharmaceutical compositions for the prophylaxis and/or treatment of premature baby anemias, anemias associated with chronic renal insufficiency, anemias following chemotherapy and anemias in HIV patients.

15. The use as claimed in one of claims 10 to 13 for preparing medicaments or pharmaceutical compositions for stimulating the erythropoiesis of individuals donating their own blood.

16. The use of erythropoietin sensitizers for preparing medicaments or pharmaceutical compositions for the prophylaxis and/or treatment of anemias.

17. The use as claimed in claim 16 for preparing medicaments or pharmaceutical compositions for the prophylaxis and/or treatment of premature baby anemias, anemias associated with chronic renal insufficiency, anemias following chemotherapy and anemias in HIV patients.

18. The use of erythropoietin sensitizers for preparing medicaments or pharmaceutical compositions for stimulating the erythropoiesis of individuals donating their own blood.

- 57 -

Amend.

A³

Add

A⁴

19. The use as claimed in one of claims 16 to 18, characterized in that the ~~erythropoietin~~ sensitizers are administered orally.

1001697 20000001